Published in final edited form as:

Pharmacol Biochem Behav. 2011 August ; 99(2): 275–284. doi:10.1016/j.pbb.2010.11.020.

Cognitive Enhancers for Anxiety Disorders

Stefan G. Hofmann, Ph.D.¹, Jasper A. J. Smits, Ph.D.², Anu Asnaani, M.A.¹, Cassidy A. Gutner, M.A.¹, and Michael W. Otto, Ph.D.¹

¹ Boston University

² Southern Methodist University

Abstract

Cognitive behavioral therapy is an effective intervention for anxiety disorders. However, a significant number of people do not respond or only show partial response even after an adequate course of the treatment. Recent research has shown that the efficacy of the intervention can be improved by the use of cognitive enhancers that augment the core learning processes of cognitive-behavior therapy. This manuscript provides a review of the current state of cognitive enhancers for the treatment of anxiety disorders.

Keywords

cognitive enhancer; anxiety; fear; cognitive behavioral therapy

Introduction

The most effective treatment for anxiety disorders is cognitive-behavioral therapy (CBT), which is typically administered in form of 12 to 15 weekly sessions (e.g., Cape, Whittington, Buszewicz, Wallace, & Underwood, 2010; Gould, Otto, & Pollack, 1995; Hofmann & Smits, 2008; Stewart & Chambless, 2009). The CBT model posits that dysfunctional cognitions are causally linked to emotional distress, and that correcting these dysfunctional cognitions result in improvement of emotional distress and maladaptive behaviors. CBT is a short-term individual or group treatment that is typically administered over the course of weekly 1-hour treatment sessions. The treatment consists of several distinct but interwoven treatment components. The therapy introduces cognitive restructuring techniques and the exposure rationale. Specifically, patients practice identifying maladaptive cognitions (automatic thoughts), observing the covariation between anxious mood and automatic thoughts, examining the errors of logic, and formulating rational alternatives to their automatic thoughts. Patients are further asked to identify avoidance strategies and to eliminate them while exposing themselves to anxiety-provoking situations that appear to violate their personal social standards. Patients then confront increasingly difficult feared situations while applying cognitive restructuring techniques and eliminating any forms of avoidance strategies. Behavioral experiments are utilized to confront specific reactions to exposure experiences. Alternative therapies include traditional (anxiolytic) pharmacological agents, including include selective serotonin reuptake inhibitors (SSRIs), monoamine

Corresponding Author: Dr. Stefan G. Hofmann, Department of Psychology, Boston University, 648 Beacon Street, 6th Floor, Boston, MA 02215-2002, Fax: (617) 353-9609, Tel: (617) 353-9610.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

oxidase inhibitors (MAOIs), tricyclic antidepressants and benzodiazepines (e.g., Baldwin et al., 2005).

Although both treatment modalities are efficacious, there is clearly room for improvement (Hofmann & Smits, 2008). For example, a complete analysis of placebo-controlled CBT trials showed an average treatment effect size of only 0.73. On the other hand, the success of this brief-treatment approach in the face of such chronicity is a testament to the degree to which patients learn in response to the informational, cognitive-restructuring, and exposure (extinction learning) based interventions offered in these protocols. Moreover, this learning occurs despite the presence of memory deficits that can be associated with the anxiety disorders (Airaksinen, Larsson, & Forsell, 2005; Asmundson, Stein, Larsen, & Walker, 1994–1995).

Similar treatment effects have been found for pharmacotherapy trials (Roy-Byrne & Cowley, 2002). In order to enhance the efficacy of these treatments, a number of studies have examined the efficacy of combination strategies. However, a meta-analysis comparing combination strategies (CBT plus anxiolytic medication) with CBT plus placebo only showed modest benefits of combination strategies immediately after treatment (effect size: 0.59) and no added benefit at 6-month follow-up (Hofmann, Sawyer, Korte, & Smits, 2009). Furthermore, partial, or non-response, to treatment remains an all-too-common occurrence, with over half of patients failing to respond fully to first-line CBT or pharmacologic interventions (Pollack et al., 2008). Recently, the search for new strategies to augment treatment has turned to a unique model of combination therapy. Rather than using pharmacotherapy as an anxiolytic in its own right, it is used to augment the core learning processes of cognitive-behavior therapy (Davis, Barad, Otto, & Southwick, 2006; Hofmann, 2007). A particularly successful prototype of such an augmentation strategy of CBT is the use of d-cycloserine (DCS; Norberg, Krystal & Tolin, 2008; Hofmann, 2007). This goal of this manuscript is to provide a review of the nature and success of cognitive enhancers for the treatment of anxiety disorders.

1. DCS and the Augmentation of Extinction Learning

In a particular success of translational research (Anderson & Insel, 2006), the application of DCS as an augmentation strategy was the product of animal research on the brain circuits underlying extinction learning (for a review, see Davis, Ressler, Rothbaum, & Richardson, 2006). Extinction learning appears to be modulated by activity of the glutamatergic N-Methyl-D-Aspartate (NMDA) receptor in the amygdala. Inhibitors of this activity appear to block the retention of extinction learning (Falls, Misrendino, & Davis, 1992), and likewise, partial agonists, like DCS, enhance this learning (Walker, Ressler, Lu, & Davis, 2002). Specifically, it appears that DCS enhances the consolidation of the new learning that occurs during extinction learning; augmentation effects continue to be present when DCS is administered within several hours after extinction learning (see Richardson, Ledgerwood, & Cranney, 2004). Hence, DCS appears to act as a memory enhancer, aiding the consolidation of what was learned during extinction learning. Indeed, only animals that show effective learning during extinction training display the benefits of memory enhancement in subsequent tests (Bouton, Vurbic, & Woods, 2008).

These exciting findings from the animal laboratory were extended to the clinic in a placebo controlled trial by Ressler et al. (2004). Height phobic patients were given a single dose of study medication prior to each of two exposure sessions. Exposure was conducted using a virtual reality apparatus, and the use of only two exposure sessions mirrored animal study designs; e.g., an enhancement effect is easier to observe when an inadequate number of extinction sessions are given (cf., Walker et al., 2002). Ressler et al. (2004) found that DCS

given prior to exposure significantly enhanced extinction learning, and this effect was evident at both 1–2 weeks and 3 months after the treatment sessions. Moreover, patients who received DCS reported more exposure to heights in life, consistent with the notion that DCS may have enhanced the memory of successful exposure experiences in the virtual reality environment and hence influenced the willingness to continue such exposure.

The successful trial by Ressler and associates (2004) was followed by a number of other successful studies, starting with the application of DCS augmentation to social anxiety disorder (Hofmann et al., 2006). In that study, we randomized 27 patients with social phobia to 50 mg DCS or pill placebo. DCS was administered one hour during the final four of a five session protocol of weekly treatment. During these four sessions, patients completed social exposure exercises. Patients who had received DCS achieved significantly more benefit as evaluated at acute and one-month follow-up evaluations. This small study was subsequently replicated by Guastella et al. (2008) with a larger ($N = 56$) sample size; similar benefit for DCS administration was found. We have reported similar positive findings for the application of DCS to the treatment of panic disorder (Otto et al., 2009). In that trial, DCS or pill placebo was administered to 31 patients with panic disorder during the final 3 of a 5-session protocol. In addition to targeting patients with panic disorder, this trial was unique for relying on exposure to feared internal sensations (interoceptive exposure) as the key extinction procedure. The majority of participants (87%) had failed to respond to previous pharmacologic interventions; nonetheless, strong DCS effects (reflecting a large effect size) were found relative to placebo. Larger scale, federally funded trials are now underway to confirm these results for social anxiety disorder and panic disorder in separate, large, multisite trials. Furthermore, federally funded controlled trials are currently underway to examine the efficacy of DCS as an augmentation strategy of exposure therapy for PTSD.

As compared to augmentation of exposure-based CBT for social anxiety disorder and panic disorder, applications of DCS to obsessive compulsive disorder (OCD) have been less positive (Kushner et al., 2007; Wilhelm et al., 2008; Storch et al., 2010). These studies are marked by more intensive scheduling of exposure sessions (twice weekly) and/or a greater number of doses of DCS across treatment. The studies by Kushner et al. (2007) and Wilhelm et al. (2008) showed an initial DCS augmentation effect that weakened with continuous administration. This suggests that DCS might enhance the speed of recovery when administered acutely during CBT and thereby reduce dropouts. The only trial in which DCS did not show an augmentation effect is the study by Storch et al. (2010). Patients in this trial received 250 mg of DCS 4 hours before each of 12 CBT sessions. As discussed below, these differences in the frequency, amount, and dosing schedule of DCS may be one source of the inconsistent results in some of the studies.

1.1. Limits of DCS Augmentation: Dosing and Learning Issues

Dose response studies have not been conducted for determining the optimal dose of DCS for the enhancement of extinction learning. Ressler et al. (2004) applied single doses of either 50 mg or 500 mg DCS, and found no differences between them. Subsequent studies have applied single doses of 50, 100, and 125 mg DCS, and have found this dose adequate for enhancement of exposure therapy (Guastella et al., 2008; Kushner et al., 2007; Hofmann et al., 2006; Otto et al., 2009; Wilhelm et al., 2008). In our own studies, we in part chose 50 mg because of a desire to avoid side effects, as well as concerns about the rapid tolerance to DCS. Concerning side effects, we have observed few across our clinical and nonclinical trials, suggesting to us that patients are unlikely to be able to discriminate DCS from placebo when 50 mg doses are used. Concerning tolerance, animal research suggests that tolerance to DCS may be reached rapidly with repeated dosing (for review see Hofmann, Pollack, & Otto, 2006). For that reason, we have sought to use DCS sparingly, applying it in single doses before therapy sessions arranged one week apart. Weaker results have been found

when DCS has been applied twice a week for more extended periods and using larger doses (cf. Kushner et al., 2007, Storch et al., 2010; Wilhelm et al., 2008), but there are enough design differences between studies that attribution of these effects to dosing cannot be made reliably.

Evidence for a potential dose effect comes from a study of DCS enhancement outside of an extinction paradigm. First, we found no beneficial effects for augmentation of the learning of verbal and nonverbal stimuli. Specifically, we found that single dose applications of 50 mg DCS vs. placebo prior to weekly trials of learning complex verbal (a detailed narrative) and nonverbal (complex figures) stimuli had no effects on immediate or delayed recall in healthy participants (Otto et al., 2009). Furthermore, only limited and inconsistent positive findings of a single-dose application of 50 mg DCS was found for memory tasks in individuals with schizophrenia (Goff et al., 2008). In contrast, Onur et al. (2010) found that 250 mg DCS did offer augmentation for declarative learning (specifically, item category associative learning), reducing the number of trial repetitions needed to attain improved learning. Onur and associates linked this DCS effect to enhanced activity in the hippocampus. Accordingly, given the failure to achieve a similar effect with 50 mg by Otto et al. (2009), Onur et al. proposed that whereas 50 mg DCS may be sufficient for amygdala-dependent learning such as extinction, a higher dose may be necessary for learning more specific to hippocampal processes. Further research is needed to confirm this hypothesis. Given concerns regarding tolerance to DCS (see Hofmann, Pollack, & Otto, 2006), it is important to consider in this work the possibility that the dose-response relationship may take on a quadratic function.

Another concern about the clinical application of DCS augmentation concerns the potential for sensitization of negative memories, for example should a patient have a sensitizing experience (e.g., a car accident or a poor exposure session) after taking DCS. It would be preferable to administer DCS after completion of the exposure session, so that the memory enhancing effects of DCS could be targeted toward only the sessions judged to be successful by the clinician, but the time course of orally given DCS is such that peak doses are achieved 4 to 6 hours after ingestion. For this reason, even though the targeted activity for DCS is to be after the session, DCS is typically given one hour prior to the session, so that it is likely to be active during the hours after the session (e.g., with a 90 minute session, starting 150 minutes after the pill was taken). Despite potential limitations of this time course, testing of post-session oral administration of DCS is underway. Nonetheless, sensitizing experiences could occur after the session. In response to this issue, Davis et al. (2006) have reasoned that under fear conditioning experiences, the NMDA receptors may already be saturated, and that because DCS is a partial agonist, it may have relative inhibitory effects at times of fear. Specifically, Davis et al. (2006, p. 272) argue, "if the site on the NMDA receptors involved in fear conditioning is fully saturated, DCS might actually reduce the activity of the receptors by displacing the more effective endogenous chemicals. This could explain why DCS seems to actually inhibit fear conditioning in some situations." Recent evidence that DCS facilitation of extinction learning can be disrupted by the occurrence of a stressor (e.g., footshock) prior to DCS administration (Langton & Richardson, in press) provides support for this hypothesis. In humans, testing of the relative effects of DCS vs. placebo on positive and negative emotional stimuli is currently underway, allowing the evaluation of aspects of this hypothesis. Similarly, a number of studies are underway to examine the optimal timing of administration of DCS, providing data that has important clinical and theoretical implications.

In summary, clinical studies provide strong evidence for a role of DCS in augmenting exposure therapy for the anxiety disorders, with evidence of a medium effect size ($d = .60$) for clinical populations (Norberg et al., 2008). Additional and ongoing examination of DCS

will provide more information of the limits of this strategy and whether the very promising effects can be replicated across large samples. If so, DCS may emerge as a clinical strategy for three purposes. First, it can be applied as a strategy for reducing the number of sessions needed for treatment, a strategy of particular value in practice settings where access to CBT providers may be limited. For example, in primary care settings where limited numbers of sessions have been offered (Roy-Byrne et al., 2005), DCS augmentation may help more patients enter remission from treatment. Second, it can be applied to patients who have failed to respond adequately to standard CBT strategies, to see if additional retention of session material can aid outcome. Third, it can be applied in a targeted way to patients who are likely to have difficulty retaining the benefits of exposure therapy. For example, deficits in extinction retention have been found in schizophrenia (Holt et al., 2009), and animal studies suggests that DCS may help overcome specific extinction retention deficits, at least those that occur developmentally (e.g., McCallum, Kim & Richardson, 2010). All of these applications hold promise for decreasing the burden of anxiety disorders on affected patients. Finally, one value that successful studies of DCS augmentation offer is encouragement for further study of memory enhancement strategies to empirically-supported psychosocial treatments for anxiety. In the following sections, we review a number of candidates for these additional augmentation efforts.

2. Cortisol for the Augmentation of Extinction Consolidation

In recent years, there has been a re-conceptualization of the role of cortisol in memory. Specifically, even though chronic elevations in glucocorticoids may impair memory functioning, there is evidence, from studies of both humans and laboratory animals, that acute increases in glucocorticoids can enhance emotional consolidation and extinction-based learning (for review see Lupien et al., 2005; Otto, McHugh, & Kantak, 2010).

In animal studies, cortisol activation is linked to enhanced consolidation of memory and, specifically, enhanced extinction learning (e.g., Barreto, Volpato, & Pottinger, 2006; Yang, Chao, Ro, Wo, & Lu, 2007). While promoting new learning, acute corticosterone increases may impair reconsolidation of existing memories (Cai, Blundell, Han, Greene, & Powell, 2006; Pakdel & Rashidy-Pour, 2007) providing an additional mechanism for the creation of adaptive memories for clinical interventions.

Memory enhancing effects of cortisol have been documented in humans (e.g., Beckner, Tucker, Delville, & Mohr, 2006; Cahill, Gorski, & Le, 2003), particularly for emotional stimuli (Abercrombie, Speck, & Monticelli, 2006; Buchanan & Lovallo, 2001; Putman, Van Honk, Kessels, Mulder, & Koppeschaar, 2004). Moreover, cortisol has been linked to facilitated extinction learning in humans. Specifically, Soravia et al. (2006) examined the influence of oral cortisol (10 mg) relative to placebo on exposure to photos of a spider. Study pills were administered one hour before exposure, and this procedure was repeated six times over two weeks, with greater fear reduction in patients who had received cortisol. Furthermore, in exposure protocols, cortisol levels have been linked to clinical outcomes in patient samples. For example, Junghanns et al. (2005) found that greater cortisol reactivity during 60 minute cue exposure sessions predicted lower relapse at 6 weeks post-treatment in alcohol dependent participants. Likewise, levels of cortisol (but not specifically cortisol reactivity) predicted clinical outcomes in patients with panic disorder and agoraphobia undergoing in vivo exposure sessions (Sigmund et al., in press). Finally, salivary cortisol levels decreased in rape victims with post-traumatic stress disorder following successful exposure-based treatments for PTSD (Gerardi, Rothbaum, Astin, & Kelley, 2010). These findings are tentative and in need of replication, but they do draw attention to a potentially important role for cortisol in aiding extinction learning.

In contrast to strategies to enhance cortisol levels, many anxiolytic (benzodiazepine or antidepressant) medications suppress cortisol or hinder cortisol reactivity (e.g., Curtis, Abelson, & Gold, 1997; Fries, Hellhammer, & Hellhammer, 2006; Pomara, Willoughby, Sidtis, Cooper, & Greenblatt, 2005; Rohrer, von Richthofen, Schulz, Beyer, & Lehnert, 1994). In reviewing these data, and the above findings on cortisol levels and the facilitation of extinction memory, Otto and associates (2010) hypothesized that attenuation of glucocorticoid activity by anxiolytic medications may interfere with extinction learning in exposure-based CBT, reducing some of the benefits of traditional combination therapy when CBT and these medications are applied simultaneously. Accordingly, attention to these potential interfering effects may lead to more judicious application of combination treatments, relative to the efficacy of either strategy alone.

3. Catecholamines

3.1. Potential Role for Dopamine and Norepinephrine

Studies of nonhuman primates suggest that catecholamine modulation, especially prefrontal cortex dopamine, is implicated in higher cognition, such as working memory. For example, the D1 receptor in the dorsolateral prefrontal cortex appears to be critical to spatial working memory performance in monkeys (Sawaguchi and Goldman-Rakic, 1991). D1 receptors in the PFC primarily exist on the distal dendritic spines of pyramidal cells. D1 activation not only directly excites pyramidal neurons, but enhances the responsiveness of the post-synaptic NMDA receptor on those cells as well (Seamans and Yang, 2004). D1 receptor activation appears to attenuate the recurrent excitation, probably by presynaptic inhibition of glutamate release (Seamans and Yang, 2004). This may have the effect of constraining the extent of local activation during cognitive processes. Therefore, D1 receptor-mediated action in the PFC appears to potentiate intense focal activity, whereas dampening the responsiveness of the local surrounding circuitry that would otherwise compete with the presently active circuit (Goldman-Rakic, Castner, Svensson, Siever, & Williams, 2004). It appears that the D1 receptor activation adjusts the gain (i.e., the strength of the representation) of the glutamate-encoded information in the PFC (Seamans and Yang, 2004), which includes a depression of background PFC activity. This then serves to make the self-sustained activity robust to noise and distractors (Durstewitz and Seamans, 2002).

In addition to working memory and cognition, dopamine has demonstrated a clear implication of its role in other various important brain processes such as motivation and reward seeking. In the anxiety disorders, there appears to be an inhibitory effect on dopaminergic activity in response to activity of two other neurotransmitters, GABA and serotonin. As a result, there has been observed to be an over-activity of dopamine in brain regions implicated in the maintenance of anxiety pathology when there is a deficiency of serotonin or GABA (Nikolaus, Antke, Beu, & Muller, 2010). Specifically, neuroimaging and lesion studies reveal that a higher binding potential at dopamine receptors in brain areas such as the mesolimbic and striatal regions seem to be related to a greater frequency of anxiety and compulsion-related disorders (de la Mora, Gallegos-Cari, Arizmendi-Garcia, Marcellino, & Fuxe, 2010; Olver et al., 2009; Stein & Ludik, 2000). Similar patterns in dopaminergic receptors have been observed in these brain regions in individuals reporting symptoms of generalized social anxiety (van der Wee et al., 2008; Sareen et al., 2007; Furmark, 2009).

Given this observed relationship between dopamine transmission and anxiety symptoms, investigators have turned their attention to either directly or indirectly manipulating dopamine availability in relevant brain areas. Indirect methods have included use of serotonin-reuptake inhibitors for disorders such as OCD, in order to increase synaptic serotonin which would in turn inhibit dopamine release, but these drugs have not been found

to be satisfactorily effective when used alone (Koo, Kim, Roh & Kim, 2010). Given the observation of higher binding potential of dopamine to its receptors in the striatal regions of the brain, direct methods that target the blockade of these dopamine receptors by dopamine antagonists to ideally produce anxiolytic effects would be a promising area to explore further, particularly for reduction in symptoms of OCD and generalized social anxiety. Indeed, preclinical studies indicate that such antagonists may be helpful in reducing dopamine activity, but this still warrants attention in clinical samples to see whether this translates to a reduction in anxiety symptoms.

Norepinephrine is implicated in PFC-dependent cognitive functions. For example, α_2 receptors modulate working memory performance in monkeys and rodents. These effects probably occur at post-synaptic sites (Arnsten and Goldman-Rakic, 1985). It has been suggested that phasic locus coeruleus activity is driven by the outcome of task-related decision processes that are signaled by descending projections from the ACC and orbitofrontal cortex (Aston-Jones & Cohen, 2005). This then adjusts the gain in target neurons via ascending projections back to the PFC. One implication of the inverse relationship between phasic and tonic activity is that α_2 agonists could act either at the cell-body autoreceptor to adjust the balance of phasic to tonic LC activity in a manner to optimize decision-making performance or at the post-synaptic α_2 receptor to enhance sustained PFC activity (Arnsten, 2004).

3.2. Yohimbine and Extinction Learning

One other potential candidate for stimulating mPFC activity is yohimbine hydrochloride, a selective competitive α_2 -adrenergic receptor antagonist. Yohimbine increases extracellular levels of norepinephrine in this region by blocking autoreceptor inhibition of norepinephrine release (see Holmes & Quirk, 2010). Initial studies examining the effect of yohimbine hydrochloride on extinction learning have yielded mixed results. On the positive side, in an early rodent study, systemic administration of yohimbine hydrochloride resulted in a speeding up of extinction learning during massed exposure and successful fear extinction with spaced extinction trials, which usually yield minimal extinction learning relative to massed trials (Cain et al., 2004).

In an important study in humans, Powers and colleagues (Powers, Smits, Otto, Sanders, & Emmelkamp, 2009) showed evidence in support of the use of yohimbine hydrochloride for augmenting exposure-based treatment. They randomly assigned 24 adults with claustrophobic fears to receive two sessions of exposure treatment after administration of yohimbine hydrochloride (10.8 mg) or two sessions of exposure treatment after administration of a pill placebo. Consistent with hypothesis, participants who received yohimbine-augmented exposure showed better outcomes relative to those who received pill placebo-augmented exposure. Importantly, yohimbine hydrochloride was well tolerated. However, as reviewed by Holmes & Quirk (2010), a number of other animal studies have not replicated the yohimbine augmentation effect, and some have even shown impairment in extinction learning.

In their detailed accounting of both the potential benefits and limitations of yohimbine augmentation, Holmes and Quirk (2010) draw attention to differential results that may be due to mouse strain-related differences in the alacrity of extinction learning, the paradigm (e.g., bar pressing vs. freezing behaviors) used to assess extinction learning, as well as the possibility that yohimbine augmentation may be especially sensitive to the context dependence as compared to cue-focused aspects of fear stimuli (see Morris & Bouton, 2007). Holmes and Quirk raised questions whether the potential beneficial effects of yohimbine augmentation occur through the assumed noradrenergic (α_2 adrenoreceptor) stimulation as compared to alternative (5-HT_{1a} or D₂) mechanisms. Another potential

limitation of yohimbine is its tolerability. That is, although Powers et al. (2009) did not observe any adverse events in their study, there is work suggesting that yohimbine can be panicogenic when administered at doses over 10.8 mg, especially among individuals who fear somatic arousal (Charney, Heninger, & Breier, 1984; Charney, Woods, Goodman, & Heninger, 1987). At the same time, it is possible that such side effect profile (e.g., somatic arousal, panic) in fact aids the therapeutic effects of yohimbine. Specifically, interoceptive exposure, or the repeated confrontation to feared bodily sensations (e.g., racing heart, rapid breathing, dizziness), has been shown to be efficacious for treating panic and related disorders (Hofmann & Smits, 2008), presumably because it results in the extinction of fears of somatic arousal. In summary, yohimbine has shown early promise in a clinical trial in phobic humans (Powers et al., 2009), but much work needs to be done to clarify the reliability as well as the mechanism of these effects.

3.3. Modafinil

Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide; brand name Provigil in the United States) exhibits effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action (Minzenberg & Carter, 2008). Modafinil is a wakefulness promoting agent. It is currently approved by the FDA for treating excessive sleepiness as part of narcolepsy, shift work sleep disorder and obstructive sleep apnea/hypopnea syndrome. In addition to its application for sleep disorders, it has been used off-label as a psychostimulant for the treatment of cognitive dysfunction in some psychiatric conditions, such as schizophrenia, attention-deficit/hyperactivity disorder (Minzenberg & Carter, 2008), and a general cognitive enhancer in normals (Volkow et al., 2009).

Preclinical data suggest that modafinil can improve working memory performance in a dose- and delay-dependent manner, that the processing of contextual cues is enhanced with modafinil, and that these effects may be augmented with sustained dosing regimens (for a review, see Minzenberg & Carter, 2008). Human studies have shown that modafinil enhances working memory, recognition memory, sustained attention, and other tasks dependent on cognitive control in healthy subjects (with or without undergoing sleep deprivation). Among psychiatric populations, there is some evidence that modafinil improves attention and response inhibition in children and adolescents with ADHD. Other studies suggest that, as mentioned above, modafinil improves several prefrontal-dependent cognitive functions in schizophrenia, major depression, and adult ADHD.

Modafinil appears to be associated with greater anxiety in both animal and humans, but the evidence is mixed and might be dose-dependent. Whereas amphetamine increased measures of anxiety in mice (increased latency of exploration of a white compartment, increased open-field thigmotaxis, and decreased time in the open arms of an elevated-plus maze), modafinil did not show these effects at doses that induce comparable effects on locomotor activity (Simon, Pannissaud, & Costentin, 1994). A study in monkeys found no effect of modafinil on anxiety after single or repeated doses that increased nocturnal activity (Hermant, Rambert, & Duteil, 1991). A pharmacokinetic study of modafinil in healthy humans reported heightened anxiety at doses from 200–800 mg (Wong et al., 1999). Another study of mood and cognitive function in healthy young adults found that a single 100 mg dose of modafinil was associated with greater subjective and physical symptoms of anxiety than placebo, but a higher dose (200 mg) did not show these effects (Randall, Shneerson, Plaha, & File, 2003). In contrast, healthy adults who received modafinil 400 mg daily for 3 days reported being less calm than those receiving a placebo (Taneja, Harman, Shelton, & Robertson, 2007). Similarly, placebo-controlled studies found that repeated administration of modafinil was associated with greater anxiety in myotonic dystrophy

patients (MacDonald, Hill, & Tarnopolsky, 2002), obstructive sleep apnea (Schwartz, Hirshkowitz, Erman, & Schmidt-Nowara, 2003), and multiple sclerosis patients (Zifko, Rupp, Schwarz, Zipko, & Maida, 2002). In sum, the literature suggests that that modafinil is associated with increased anxiety in healthy individuals and clinical populations. Its potential role in augmenting extinction learning (and the potential role of enhanced anxiety in this process) remains to be studied.

4. Nutrients and Botanicals

Another area warranting investigation is the use of natural compounds as adjunct enhancers of traditional anxiety treatments. Indeed, several studies have tested naturally occurring compounds such as omega-3 fatty acids, caffeine, and nicotine for their effects on the fear system and anxiety disorder symptoms. A brief overview of the findings for each of these substances is given below.

4.1. Caffeine

Caffeine is one of the most widely consumed substances in the class of psychostimulants, which are part of the larger family of methylxanthine compounds. The primary site of action for the substance is at adenosine receptors, where caffeine has been shown to modulate brain activity and cerebral blood flow (Chen & Parrish, 2009). Further, there appears to be a dose-response effect with caffeine such that low to moderate consumption patterns are associated with increased alertness and mental focus, while high dosages have been implicated in the exacerbation of negative feelings such as insomnia and anxiety (Yun, Doux, & Daniel, 2007). In addition, evidence points to a heightened sensitivity and reactivity to caffeine in individuals reporting histories of panic attacks as compared to controls (Boulenger, Uhde, Wolff, & Post, 1984). Specifically, patients with panic disorder or agoraphobia have reported significantly higher ratings of fear and physical symptoms (e.g. trembling, palpitations, nausea, and tremors) when administered equal doses of caffeine as control subjects, and these symptoms were significantly correlated to plasma caffeine levels (Charney, Heninger, & Jatlow, 1985). Similar observations have been made in social phobics fearing public performance situations, although with mixed results for generalized social anxiety cases (Nardi et al. 2008; Aouizerate, Martin-Guehl, & Tignol, 2004). This, with other studies directly measuring adenosine receptor activity with caffeine administration, have strongly suggested a link between fear of physical symptoms and a particular sensitivity to caffeine-induced neural activity at adenosine receptor sites (DeMet et al, 1989; Nardi et al., 2007).

In order to better parse out how caffeine may impact the fear and alarm circuitry, several studies have used caffeine challenge tasks with individuals meeting criteria for panic disorder. Typically such experimental paradigms have involved administering various dosages of caffeine to subjects (e.g. 200 mg – 400 mg), and then measuring performance on another task aimed to mimic the symptoms typically experienced during panic attacks, such as breath holding (BH), CO₂ inhalation, and hyperventilation. Results of such experimental set-ups have primarily revealed a reduced capacity to tolerate the unpleasant physical symptoms generated by such tasks in individuals with panic disorder histories who have consumed caffeine, but no differences as a result of caffeine intake in those with no such anxiety history (Masdrakis, Markianos, Vaidakis, Papakostas, & Oulis, 2009). Others have hypothesized a beneficial application of caffeine in the treatment of anxiety, such as in exposure therapy for spider phobia, where participants were administered either caffeine or placebo at the time of an exposure session and then again at a one-week follow-up visit, where they were assessed for return of fear (Mystkowski, Mineka, Vernon, & Zinbarg, 2003). The results indicated that those individuals experiencing congruent drug states (i.e. ingestion of caffeine at both test and follow-up periods) exhibited significantly less return of

fear than those in incongruent drug states. However, this was also true of the placebo group, therefore this study provided evidence more generally for state-dependent learning in extinction of fear, and not specifically for an additive benefit of augmentation with caffeine.

4.2. Omega-3 Fatty Acids

Mammalian brain tissue is primarily comprised of lipids which are themselves composed of combinations of saturated, monosaturated, and polyunsaturated fatty acids. Several key omega-3 fatty acids (i.e. α -linolenic acid or ALA, and linoleic acid) can be synthesized quite readily from foods such as flaxseed, canola, and soy. Others (particularly docosahexaenoic acid or DHA, which makes up some 10–20% of brain fatty tissue) are not easily synthesized from dietary sources, but are obtained in preformed fashion from sources such as fatty fish (e.g. tuna and salmon) (McNamara & Carlson, 2006). In animal models, deficiencies in these brain matter constituents are associated with neurocognitive deficits, elevated aggression, anxiety, and depression levels, and deficits in primary neurotransmitter transmission such as dopamine and serotonin.

In humans, the effect of this deficiency looks a little different. Specifically, a deficit in fatty acids (as seen most typically in pre-term babies) has been implicated in increased risk for attention-based pathology such as attention deficit/hyperactivity disorder (ADHD), other psychopathology such as schizophrenia, and in deficits in cortical gray matter maturation. On the whole, the work on omega-3 fatty acid levels in human populations has been scant thus far, but preliminary evidence indicates that deficiencies in this particular substance may be associated with higher incidence of depression in human populations, as observed in animal studies (Timonen et al., 2004; Klok, Gotestam, Mykletun, 2010). A handful of studies have investigated the effects of baseline omega-3 levels on responsiveness to traditional SSRIs in treatment of depression, but the results of these studies have not indicated a clear added benefit of taking a supplement of omega-3 (Fiedorowicz, Hale, Spector, Coryell, 2010). The beneficial use of omega-3 supplements has been even less frequently examined in the anxiety disorders, but given the relatively supported link of omega-3 deficiency to elevated indices of anxiety in animals, this would be a potentially fruitful avenue to explore further.

4.3. Nicotine

Nicotine has been widely understood to be positively linked to psychiatric disorders such as schizophrenia, depression, and certain anxiety disorders. In particular, researchers have noted a higher incidence of smokers in the population of individuals diagnosed with panic disorder (Breslau & Klein, 1999). Others have actually found a lower incidence of nicotine dependence in individuals meeting criteria for OCD, thus creating a mixed picture of the specific effects of nicotine on the fear and alarm system. Pre-clinical studies on the effects of nicotine on non-human species have suggested a dose-response relationship of nicotine to anxiety such that low doses are associated with anxiolytic effects and higher doses are associated with anxiogenic effects (Brioni, O'Neill, Kim, & Decker, 1993; File, Kenny, & Ouagazzal, 1988). Others have suggested that the anxiolytic properties of nicotine are more readily linked to other factors such as whether the animal is tested on a task such as the elevated plus maze which more readily models specific phobia, as compared to the anxiogenic effects of the substance on other tasks such as social interaction tasks (File, Cheeta, & Kenny, 2000).

Such findings could elucidate how nicotine's effects may be best understood as disorder-specific, and explain some of the clinical observations of relative rates of nicotine dependence across the anxiety disorders. Several human studies have adopted paradigms similar to those seen with caffeine whereby non-smoking individuals are administered small

doses of nicotine transdermally (via a patch) before they undergo a CO₂ inhalation task. While nicotine increased physiological arousal (e.g. blood pressure and heart rate), it did not induce panic in healthy subjects (Cosci, Abrams, Schruers, Rickelt, & Griez, 2006). Yet, other smaller studies with clinical populations have indicated some reduction in the compulsive symptoms of OCD with transdermal administration of nicotine (Salin-Pascual & Basanez-Villa, 2003). Overall, it is clear that more exploration in both normal and clinical populations is required to better parse out whether particular dosages of nicotine may actually be beneficial in tempering the fear response in anxiety patients.

4. Novel Treatment Approaches and Future Directions

4.1. Methylene Blue

A brain region that appears critical to the consolidation of extinction memory is the medial prefrontal cortex (mPFC; Quirk, Garcia, & Gonzalez-Lima, 2006). Indeed, studies have demonstrated that lesions of the ventral mPFC do not hamper extinction learning per se, but result in impairments of extinction retention (Quirk, Russo, Barron, & Lebron, 2000; Lebron, Milad & Quirk, 2004; Morgan, Romanski, & LeDoux, 1993). Both rodent and human studies have further shown that extinction recall is associated with significant activation of the mPFC region (Barrett, Shumake, Jones, & Gonzalez-Lima, 2003; Milad & Quirk, 2002; Milad, Vidal-Gonzalez, & Quirk, 2004) and that stimulation of the mPFC enhances extinction retention in rodents (Herry & Garcia, 2002; Milad & Quirk, 2002; Milad et al., 2004). Together, these studies support the development of strategies that target mPFC activity.

One approach to enhancing fear extinction through the stimulation of mPFC activity that has received some initial empirical support is the administration of methylene blue (MB; Gonzalez-Lima and Bruchey, 2004). As opposed to DCS, which targets a specific transmitter system, the action of MB is non-specific. MB can activate the mPFC region by its effects on brain cytochrome oxidase activity. Specifically, by increasing brain cytochrome oxidase activity, MB improves oxidative energy metabolism and can thereby supply the energy needs of synapses involved in extinction memory consolidation (Gonzalez-Lima and Bruchey, 2004). In an initial rodent study, Gonzalez-Lima and Bruchey (2004) demonstrated that post-extinction administration of MB (4mg/kg intraperitoneally) was associated with greater extinction retention as well as increased brain cytochrome oxidase activity, particularly in the prefrontal cortical region. Clinical studies on the efficacy of MB for augmenting exposure-based treatment are currently underway.

4.2. Endocannabinoids

The endogenous cannabinoid (or endocannabinoid) system has become another focus of research investigating novel therapeutic approaches for anxiety and related disorders (Porter & Felder, 2001). This research has largely been done due to the large presence of CB1 receptors in brain regions related to anxiety and emotional learning in general (e.g., amygdala, hippocampus). There are two types of cannabinoid receptors, CB1 and CB2. CB1 is most often in the peripheral and central nervous system, while CB2 receptors are involved more in the immune and enteric nervous system, as well as in glial cells in the central nervous system. Studies on humans and animals have shown that cannabinoid agonists have an anxiolytic effect that is dose dependent. Lower doses have been shown to produce an anxiolytic effect in animals whereas higher doses result in an anxiogenic effect (Viveros, Llorente, Moreno, & Marco, 2005; Pacher, Batkai, & Kunos, 2006). With respect to anxiety and depression, human studies of depression, which is often comorbid with anxiety, have demonstrated involvement of CB1 (Vinod & Hungund, 2006). In fact, CB1 antagonists are being explored as a potential treatment for depression (Stein, Ipser, & Seedat, 2006) due to

the interaction of cannabinoids and conditioned fear. The cannabinoid system modulates basal anxiety and appears to be involved in the conditioned fear. Additionally, cannabinoid neurotransmitters effect both acquisition and the expression of fear conditioning (Haller, Bakos, Szirmay, Ledent, & Freund, 2002) in that CB1 antagonists decrease acquisition of contextual fear conditioning involving the amygdala and hippocampus (Arenos, Musty, & Bucci, 2006).

This system has been linked to extinction learning in animal models (e.g., Chhatwal et al., 2009; Marsicano et al., 2002). As discussed above, extinction learning is the foundation for most empirically supported treatments for anxiety disorders. CB1 antagonists lead to significant deficits in extinction learning, indicating that CB1 activation is necessary for extinction learning to occur, and therefore CB1 agonists serve as an opportune novel augmentation treatment (Chhatwal, Davis, Maguschak, & Ressler, 2005).

4.3. Genetic Modulation

4.3.1. BDNF—Changes or alteration in gene expression have recently provided great insight into the processes of learning in memory. One recent focus has been on brain-derived neurotrophic factor (BDNF), which is part of the neurotrophin family of growth factors. BDNF affects the adult central nervous system and, within this system, plays a role in synaptic plasticity of neurons involved in learning and memory (Egan et al., 2003; Hariri et al., 2003). BDNF is involved in fear and extinction learning and serves a central function in the biological substrates of psychological disorders (Charney & Maniji, 2004; Nestler et al., 2002). Fear learning is built off the ability to recognize and remember safety and threat cues to achieve extinction learning. Moreover, this type of learning is impaired in anxiety disorders (e.g., Rauch, Shin, & Phelps, 2006; Lissek et al., 2005). Animal research has demonstrated that both genetic and pharmacological inhibition of BDNF signaling leads to a significant reduction in long term potentiation, ultimately leading to memory impairments across a variety of memory tasks (see Yu et al., 2009). Regarding fear extinction learning, there is now evidence in animal populations to suggest that BDNF mediates consolidation of extinction memory within the infralimbic medial prefrontal cortex (IL mPFC).

The hypothesis that the efficacy of exposure-based treatments can be enhanced with strategies that increase hippocampal BDNF also receives support, albeit indirect, from a study involving human participants. Kobayashi and colleagues (2005) provided 42 outpatients with panic disorder with manualized cognitive-behavioral treatment (CBT) and found that patients with poor response to CBT had significantly lower serum BDNF levels (25.9 ng/ml [S.D. 8.7]) relative to patients with good response to CBT (33.7 ng/ml [S.D. 7.5]). In addition to pharmacological options to increase hippocampal BDNF, growing evidence supports the use of aerobic exercise for this application (Berchtold, Castello, & Cotman, 2010; Cotman and Berchtold, 2002). Here, it is noteworthy that Ströhle and colleagues (2010) found that a 30-minute bout of moderate-intensity exercise ameliorated reduced BDNF concentrations in patients with panic disorder. These findings have formed the basis of ongoing studies testing whether exercise can be a non-pharmacological cognitive enhancer of exposure-based treatment in adults with anxiety disorders.

Given the previously discussed findings, it is not surprising that studies suggest that the BDNF_{Met} polymorphism contributes to impairments in memory extinction (Yu et al., 2009). However, when animals are given a single dose of DCS (as discussed previously), they are able to recover from this deficit across future trials. Such evidence suggests that the impairment caused by BDNF_{Met} and its potential impact on fear-based learning may be reversible.

Research on humans has identified a single nucleotide polymorphism in the BDNF gene (Val66Met) that influences hippocampal volume and hippocampal dependent memory (Egan et al., 2003; Hariri et al., 2003; Bueller et al., 2006). This human specific BDNF nucleotide (BDNF_{Met}) has been an area of interest due to the role it plays in vulnerability to psychological disorders, including anxiety and depression (Momose et al., 2002; Sklar et al., 2002; Ventriglia et al., 2002; Sen et al., 2003). The translation of the effect of BDNF polymorphisms from animals to humans supports the idea that extinction learning is impaired in both mice and humans in BDNF_{Met} allele carriers. Imaging research has demonstrated less ventromedial prefrontal cortical activity and greater amygdala activation in BDNF_{Met} allele carriers (Soliman et al., 2010). This research suggests a hypo-responsiveness in BDNF_{Met} allele carriers in brain regions crucial for extinction learning.

In sum, BDNF plays an important role in fear-based learning as demonstrated by BDNF polymorphisms. Understanding the effect of the BDNF_{Met} allele on extinction learning leads to a clearer conceptualization of treatments for anxiety, as well as novel approaches to enhancing treatment. The dysregulation of BDNF found in anxiety disorders, such as PTSD (Kaplan, Vasterling, Vedak, 2010) suggest a key role of BDNF as more research is done on the role of genetic modulation in treatment of these disorders. Moreover, the neuroregenerative effects of BDNF have the potential for reversing cognitive and emotional deficits in not only anxiety disorders like PTSD, but also in other brain related injuries such as a traumatic brain injury.

4.3.2. KIBRA—KIBRA (also known as WWC1) is another biological marker that has recently gained popularity for its potential role in learning and memory. KIBRA was first described by Kremerskothen and colleagues (2003) and is a molecule that is involved with the postsynaptic protein dendrin. KIBRA has been shown to play a key genetic role in memory and cognition (Papassotiropoulos et al., 2006). In adults it is most commonly expressed in the kidney and brain, and in both rodents and humans it is prominent in memory-related structures, such as the hippocampus, cortex, cerebellum and the hypothalamus (Johannsen, Duning, Pavenstadt, Kremerskothen, & Boeckers, 2008). Carriers of certain KIBRA T alleles (e.g., rs17070145, rs6439886) perform significantly better on tasks involving multiple episodic memories compared to individuals that are homozygous for the C allele at either polymorphism (see, Schneider et al, 2010, for a review). Moreover, functional magnetic resonance imaging studies have found greater brain activation in brain areas associated with memory retrieval in WWC1 (rs17070145) T-allele-noncarriers as compared to T-allele carriers on an episodic memory task, suggesting a strong effect of genetic contribution to certain types of memory.

The majority of research on KIBRA has involved healthy controls with and without certain T alleles and individuals with dementia. The use of KIBRA has been investigated as a potential focus for new pharmacological approaches to improve cognition. Although studies to date have not focused on anxiety and depression, KIBRA offers a new genetic link to cognition that may be of benefit beyond diseases such as Alzheimer's. In fact, it may aid in memory impairments that accompany various anxiety disorders that prevent patients from effectively engaging in empirically supported treatments, such as cognitive behavioral therapy.

6. Summary and Conclusion

Our review of cognitive enhancers for CBT of anxiety disorders includes d-cycloserine, methylene blue, catecholamines (dopamine and norepinephrine), yohimbine, modafinil, endocannabinoids, cortisol, and nutrients and botanicals (omega-3 fatty acids, caffeine, and nicotine), as potential cognitive enhancers. Of these substances, d-cycloserine has

demonstrated so far the greatest potential. We further examined BDNF and KIBRA as potentially important biological markers of treatment efficacy and genetic modulators. Our review points to the NMDA receptor complex as the most promising target for future cognitive enhancers of CBT for anxiety disorders.

Traditional treatment strategies combining anxiolytic agents, such as SSRIs, and psychological interventions, such as CBT, have been yielding disappointing results. In general, it has been found that combination treatments are not more effective than monotherapies (Hofmann, Sawyer, Korte, Smits, 2009). Moreover, and more importantly, the traditional combination approach has been conducted without a clear theoretical justification, given that the mechanisms of treatment action are not well understood for either modality. In contrast, combining CBT with cognitive enhancers is a neuroscience-based approach with the goal to translate basic research into clinical practice. This strategy offers considerable advantages over traditional combination strategies, because cognitive enhancers target specific mechanisms of the treatment process. Such strategies may be associated with greater efficacy than traditional combination treatments and monotherapies. Moreover, this may answer important questions about the mechanism of treatment change, which, in turn, can provide new questions for future research. Although the development and maintenance of anxiety disorders in humans are still issues of current controversy (e.g., Poulton & Menzies, 2002), the review of this literature and other evidence (Hofmann, 2008) suggests that cognitive processes are important factors in the treatment of these debilitating conditions.

research highlights are as follows

- We review agents that might act as cognitive enhancers for cognitive behavioral therapy for anxiety disorders in humans
- We review d-cycloserine, cortisol, catecholamines, nutrients, botanicals, methylene blue, and endocannabinoids as possible cognitive enhancers
- D-cycloserine is the most promising agent to augment extinction learning in animals and cognitive-behavioral therapy in humans.
- We examine the mechanism of cognitive enhancers and explore the role of genetic modulation.

Acknowledgments

Work on this manuscript was supported in part by MH078308 to Dr. Hofmann, MH075889 to Dr. Smits, and MH081116 to Dr. Otto. Drs. Hofmann, Otto and Smits have received consulting and/or research support from Organon (Merck/Schering-Plough). Dr. Otto has received royalties for use of the SIGH-A from Lilly.

References

- Abercrombie HC, Speck NS, Monticelli RM. Endogenous cortisol elevations are related to memory facilitation only in individuals who are emotionally aroused. *Psychoneuroendocrinology*. 2006; 31:187–96. [PubMed: 16225997]
- Airaksinen E, Larsson M, Forsell Y. Neuropsychological functions in anxiety disorders in population-based samples; Evidence of episodic memory dysfunction. *J Psychiatr Res*. 2005; 39:207–14. [PubMed: 15589570]
- Anderson KC, Insel TR. The promise of extinction research for the prevention and treatment of anxiety disorders. *Biol Psychiatry*. 2006; 60:319–21. [PubMed: 16919521]
- Aouizerate B, Martin-Guehl C, Tignol J. Neurobiology and pharmacotherapy of social phobia. *Encephale*. 2004; 30:301–13. [PubMed: 15538306]

- Arenos JD, Musty RE, Bucci DJ. Blockade of cannabinoid CB1 receptors alters contextual learning and memory. *Eur J Pharmacol.* 2006; 539:177–83. [PubMed: 16716290]
- Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. *Psychopharmacology.* 2004; 174:25–31. [PubMed: 15205875]
- Arnsten AF, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. *Science.* 1985; 230:1273–76. [PubMed: 2999977]
- Asmundson GJ, Stein MB, Larsen DK, Walker JR. Neurocognitive function in panic disorder and social phobia patients. *Anxiety.* 1994–1995; 1:201–7.
- Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. *Ann Rev Neurosci.* 2005; 28:403–50. [PubMed: 16022602]
- Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bon A, Davidson JR, denBoer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. British Association for Psychopharmacology: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. *J Psychopharmacology.* 2005; 19:567–596.
- Barrett D, Shumake J, Jones D, Gonzalez-Lima F. Metabolic mapping of mouse brain activity after extinction of a conditioned emotional response. *J Neurosci.* 2003; 23:5740–49. [PubMed: 12843278]
- Barreto RE, Volpato GL, Pottinger TG. The effect of elevated blood cortisol levels on the extinction of a conditioned stress response in rainbow trout. *Horm Behav.* 2006; 50:484–488. [PubMed: 16875691]
- Beckner VE, Tucker DM, Delville Y, Mohr DC. Stress facilitates consolidation of verbal memory for a film but does not affect retrieval. *Behav Neurosci.* 2006; 120:518–527. [PubMed: 16768603]
- Berchtold NC, Castello N, Cotman CW. Exercise and time-dependent benefits to learning and memory. *Neuroscience.* 2010; 167:588–97. [PubMed: 20219647]
- Boulenger JP, Uhde TW, Wolff EA 3rd, Post RM. Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. *Arch Gen Psychiatry.* 1984; 41:1067–71. [PubMed: 6497568]
- Bouton ME, Vurbic D, Woods AM. D-cycloserine facilitates context-specific fear extinction learning. *Neurobiol Learn Mem.* 2008; 90:504–10. [PubMed: 18672079]
- Breslau N, Klein DF. Smoking and panic attacks: an epidemiologic investigation. *Arch Gen Psychiatry.* 1999; 56:1141–7. [PubMed: 10591292]
- Brioni JD, O'Neill AB, Kim DJ, Decker MW. Nicotinic receptor agonists exhibit anxiolytic like effects on the elevated plus-maze test. *Eur J Pharmacol.* 1993; 238:1–8. [PubMed: 8405072]
- Buchanan TW, Lovallo WR. Enhanced memory for emotional material following stress-level cortisol treatment in humans. *Psychoneuroendocrinology.* 2001; 26:307–17. [PubMed: 11166493]
- Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta JK. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. *Biol Psychiatry.* 2006; 599:812–5. [PubMed: 16442082]
- Cahill L, Gorski L, Le K. Enhanced human memory consolidation with post-learning stress: interaction with the degree of arousal at encoding. *Learn Mem.* 2003; 10:270–4. [PubMed: 12888545]
- Cai WH, Blundell J, Han J, Greene RW, Powell CM. Postreactivation glucocorticoids impair recall of established fear memory. *J Neurosci.* 2006; 26:9560–6. [PubMed: 16971540]
- Cain CK, Blouin AM, Barad M. Adrenergic transmission facilitates extinction of conditional fear in mice. *Learn Mem.* 2004; 11:179–87. [PubMed: 15054133]
- Cape J, Whittington C, Buszewicz M, Wallace P, Underwood L. Brief psychological therapies for anxiety and depression in primary care: meta-analysis and meta-regression. *BMC Med.* 2010; 25:38. [PubMed: 20579335]
- Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. *Arch Gen Psychiatry.* 1984; 41:751–763. [PubMed: 6742977]
- Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. *Arch Gen Psychiatry.* 1985; 42:233–43. [PubMed: 2983630]

- Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. *Science STKE*. 2004; 225:re5.
- Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. *Am J Psychiatry*. 1987; 144:1030–1036. [PubMed: 3037926]
- Chen Y, Parrish TB. Caffeine dose effect on activation-induced BOLD and CBF responses. *Neuroimage*. 2009; 46:577–83. [PubMed: 19289172]
- Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. *Neuropsychopharmacology*. 2005; 30:516–24. [PubMed: 15637635]
- Chhatwal JP, Gutman AR, Maguschak KA, Bowser ME, Yang Y, Davis M, et al. Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. *Neuropsychopharmacology*. 2009; 34:509–21. [PubMed: 18580872]
- Cosci F, Abrams K, Schruers KR, Rickelt J, Griez EJ. Effect of nicotine on 35% CO₂-induced anxiety: A study in healthy volunteers. *Nicotine Tob Res*. 2006; 8:511–7. [PubMed: 16920648]
- Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. *Trends Neurosci*. 2002; 25:295–301. [PubMed: 12086747]
- Curtis GC, Abelson JL, Gold PW. Adrenocorticotrophic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. *Biol Psychiatry*. 1997; 41:76–85. [PubMed: 8988798]
- Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. *Biol Psychiatry*. 2006; 60:369–75. [PubMed: 16919524]
- Davis M, Barad M, Otto MW, Southwick S. Combining pharmacotherapy with cognitive behavior therapy: Traditional and new approaches. *J Trauma Stress*. 2006; 19:571–581. [PubMed: 17075906]
- de la Mora MP, Gallegos-Cari A, Arizmendi-García Y, Marcellino D, Fuxe K. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis. *Prog Neurobiol*. 2010; 90:198–216. [PubMed: 19853006]
- DeMet E, Stein MK, Tran C, Chicz-DeMet A, Sangdahl C, Nelson J. Caffeine taste test for panic disorder: adenosine receptor supersensitivity. *Psychiatry Res*. 1989; 30:231–42. [PubMed: 2616690]
- Durstewitz D, Seamans JK. The computational role of dopamine D1 receptors in working memory. *Neural Netw*. 2002; 15:561–72. [PubMed: 12371512]
- Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell*. 2003; 112:257–69. [PubMed: 12553913]
- Falls WA, Miserendino MJ, Davis M. Extinction of fear-potentiated startle: Blockade by infusion of an NMDA antagonist into the amygdala. *J Neurosci*. 1992; 12:854–63. [PubMed: 1347562]
- Fiedorowicz JG, Hale N, Spector AA, Coryell WH. Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram. *Ann Clin Psychiatry*. 2010; 22:157–63. [PubMed: 20680188]
- File SE, Kenny PJ, Ouagazzal AM. Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. *Behav Neurosci*. 1998; 112:1423–9. [PubMed: 9926824]
- File SE, Cheeta S, Kenny PJ. Neurobiological mechanisms by which nicotine mediates different types of anxiety. *Eur J Pharmacol*. 2000; 3(93):231–6. [PubMed: 10771018]
- Fries E, Hellhammer DH, Hellhammer J. Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. *Psychoneuroendocrinology*. 2006; 31:1278–88. [PubMed: 17097811]
- Furmark T. Neurobiological aspects of social anxiety disorder. *J Psychiatry Relat Sci*. 2009; 46:5–12.
- Gerardi M, Rothbaum BO, Astin MC, Kelley M. Cortisol response following exposure treatment of PTSD in rape victims. *J Aggress Maltreat Trauma*. 2010; 19:345–356.
- Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, et al. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. *Schizophr Res*. 2008; 106:320–7. [PubMed: 18799288]

- Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. *Psychopharmacology*. 2004; 174:3–16. [PubMed: 15118803]
- Gonzalez-Lima F, Bruchey AK. Extinction memory improvement by the metabolic enhancer methylene blue. *Learn Mem*. 2004; 11:633–40. [PubMed: 15466319]
- Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. *Clin Psychol Rev*. 1995; 15:819–44.
- Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. *Biol Psychiatry*. 2008; 63:544–9. [PubMed: 18179785]
- Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. *Eur J Neurosci*. 2002; 16:1395–8. [PubMed: 12405999]
- Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. *J Neurosci*. 2003; 23:6690–4. [PubMed: 12890761]
- Hermant JF, Rambert FA, Duteil J. Awakening properties of modafinil: effect on nocturnal activity in monkeys (*Macaca mulatta*) after acute and repeated administration. *Psychopharmacology*. 1991; 103:28–32. [PubMed: 1672457]
- Herry C, Garcia R. Prefrontal cortex long-term potentiation, but not long-term depression, is associated with the maintenance of extinction of learned fear in mice. *J Neurosci*. 2002; 22:577–83. [PubMed: 11784805]
- Hofmann SG. Cognitive processes during fear acquisition and extinction in animals and humans: Implications for exposure therapy of anxiety disorders. *Clin Psychol Rev*. 2008; 28:200–211.
- Hofmann SG. Enhancing exposure-based therapy from a translational research perspective. *Behav Res Ther*. 2007; 45:1987–2001. [PubMed: 17659253]
- Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with d-cycloserine. *CNS Drug Rev*. 2006; 12:208–17. [PubMed: 17227287]
- Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger KC, et al. Augmentation of exposure therapy for social anxiety disorder with D-Cycloserine. *Arch Gen Psychiatry*. 2006; 63:298–304. [PubMed: 16520435]
- Hofmann SG, Sawyer AT, Korte KJ, Smits JAJ. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. *Int J Cognitive Therapy*. 2009; 2:160–175.
- Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. *J Clin Psychiat*. 2008; 69:621–32.
- Holmes A, Quirk GJ. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine. *Trends Pharmacol Sci*. 2010; 31:2–7. [PubMed: 20036429]
- Holt DJ, Lebron-Milad K, Milad MR, Rauch SL, Pitman RK, Orr SP, et al. Extinction memory is impaired in schizophrenia. *Biol Psychiatry*. 2009; 65:455–63. [PubMed: 18986648]
- Johannsen S, Duning K, Pavenstädt H, Kremerskothen J, Boeckers TM. Temporal-spatial expression and novel biochemical properties of the memory-related protein KIBRA. *Neuroscience*. 2008; 155:1165–73. [PubMed: 18672031]
- Junghanns K, Tietz U, Dibbelt L, Kuether M, Jurth R, Ehrental D, et al. Attenuated salivary cortisol secretion under cue exposure is associated with early relapse. *Alcohol Alcohol*. 2005; 40:80–5. [PubMed: 15550447]
- Kaplan GB, Vasterling JJ, Vedak PC. Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. *Behav Pharmacol*. 2010; 21:427–37. [PubMed: 20679891]
- Klokk M, Gotestam KG, Mykletun A. Factors accounting for the association between anxiety and depression, and eczema: the Hordaland health study (HUSK). *BMC Dermatol*. 2010; 10:3. [PubMed: 20412596]

- Kobayashi K, Shimizu E, Hashimoto K, Mitsumori M, Koike K, Okamura N, et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005; 29:658–63. [PubMed: 15905010]
- Koo MS, Kim EJ, Roh D, Kim CH. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. *Expert Rev Neurother*. 2010; 10:275–90. [PubMed: 20136383]
- Kremerskothen J, Plaas C, Büther K, Finger I, Veltel S, Matanis T, et al. Characterization of KIBRA, a novel WW domain-containing protein. *Biochem Biophys Res Commun*. 2003; 300:862–7. [PubMed: 12559952]
- Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. *Biol Psychiatry*. 2007; 62:835–8. [PubMed: 17588545]
- Langton JM, Richardson R. The effect of D-cycloserine on immediate versus delayed extinction of learned fear. *Learn Mem*. in press.
- Lebrón K, Milad MR, Quirk GJ. Delayed recall of fear extinction in rats with lesions of ventral medial prefrontal cortex. *Learn Mem*. 2004; 11:544–8. [PubMed: 15466306]
- Lissek S, Powers AS, McClure EB, Phelps EA, Woldehawariat G, Grillon C, et al. Classical fear conditioning in the anxiety disorders: a meta-analysis. *Behav Res Ther*. 2005; 43:1391–424. [PubMed: 15885654]
- Lupien SJ, Friocco A, Wan N, Maheu F, Lord C, Schramek T, et al. Stress hormones and human memory function across the lifespan. *Psychoneuroendocrinology*. 2005; 30:225–42.
- MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. *Neurology*. 2002; 59:1876–80. [PubMed: 12499477]
- Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. *Nature*. 2002; 418:530–4. [PubMed: 12152079]
- Masdrakis VG, Markianos M, Vaidakis N, Papakostas YG, Oulis P. Caffeine challenge and breath-holding duration in patients with panic disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009; 33:41–4. [PubMed: 18930777]
- McCallum J, Kim JH, Richardson R. Impaired extinction retention of extinguished fear in adolescent rats: Effects of D-cycloserine. *Neuropsychopharmacology*. 2010; 35:2134–2142. [PubMed: 20592716]
- McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. *Prostaglandins Leukot Essent Fatty Acids*. 2006; 75:329–49. [PubMed: 16949263]
- Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. *Nature*. 2002; 420:70–4. [PubMed: 12422216]
- Milad MR, Vidal-Gonzalez I, Quirk GJ. Electrical stimulation of medial prefrontal cortex reduces conditioned fear in a temporally specific manner. *Behav Neurosci*. 2004; 118:389–94. [PubMed: 15113265]
- Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. *Neuropsychopharmacology*. 2008; 33:1477–1502. [PubMed: 17712350]
- Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. *Ann Neurol*. 2002; 51:133–6. [PubMed: 11782995]
- Morgan MA, Romanski LM, LeDoux JE. Extinction of emotional learning: contribution of medial prefrontal cortex. *Neurosci Lett*. 1993; 163:109–13. [PubMed: 8295722]
- Morris RW, Bouton ME. The effect of yohimbine on the extinction of conditioned fear; a role for context. *Behav Neurosci*. 2007; 121:501–14. [PubMed: 17592941]
- Mystkowski JL, Mineka S, Vernon LL, Zinbarg RE. Changes in caffeine states enhance return of fear in spider phobia. *J Consult Clin Psychol*. 2003; 71:243–50. [PubMed: 12699019]
- Nardi AE, Valença AM, Nascimento I, Freire RC, Veras AB, de-Melo-Neto VL, et al. A caffeine challenge test in panic disorder patients, their healthy first-degree relatives, and healthy controls. *Depress Anxiety*. 2008; 25:847–53. [PubMed: 17823963]

- Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. *Neuron*. 2002; 34:13–25. [PubMed: 11931738]
- Nikolaus S, Antke C, Beu M, Müller HW. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies. *Rev Neurosci*. 2010; 21:119–39. [PubMed: 20614802]
- Norberg MM, Krystal JH, Tolin DF. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. *Biol Psychiatry*. 2008; 63:1118–26. [PubMed: 18313643]
- Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, et al. Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. *J Affect Disord*. 2009; 114:321–6. [PubMed: 18706700]
- Onur OA, Schlaepfer TE, Kukulja J, Bauer A, Jeung H, Patin A, et al. The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. *Biol Psychiatry*. 2010; 67:1205–11. [PubMed: 20303474]
- Otto MW, Basden SL, McHugh RK, Katak KM, Deckersbach T, Cather C, et al. Effects of d-cycloserine administration on weekly non-emotional memory tasks in healthy participants. *Psychother Psychosom*. 2009; 78:49–54. [PubMed: 19018157]
- Otto MW, Tolin DF, Simon NM, Pearson GD, Basden S, Meunier SA, et al. The efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. *Biol Psychiat*. 2009; 67:365–70. [PubMed: 19811776]
- Otto MW, McHugh RK, Katak KM. Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: Medication effects, glucocorticoids, and attenuated outcomes. *Clin Psychol-Sci Pr*. 2010; 37:91–103.
- Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev*. 2006; 58:389–462. [PubMed: 16968947]
- Pakdel R, Rashidy-Pour A. Microinjections of the dopamine D2 receptor antagonist sulpiride into the medial prefrontal cortex attenuate glucocorticoid-induced impairment of long-term memory retrieval in rats. *Neurobiol Learn Mem*. 2007; 87:385–90. [PubMed: 17118678]
- Papassotiropoulos A, Stephan DA, Huentelman MJ, Hoernndli FJ, Craig DW, Pearson JV, et al. Common Kibra alleles are associated with human memory performance. *Science*. 2006; 314:475–8. [PubMed: 17053149]
- Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, et al. Novel treatment approaches for refractory anxiety disorders. *Depress Anxiety*. 2008; 25:467–76. [PubMed: 17437259]
- Pomara N, Willoughby LM, Sidtis JJ, Cooper TB, Greenblatt DJ. Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. *Psychopharmacology*. 2005; 178:1–8. [PubMed: 15338100]
- Porter AC, Felder CC. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. *Pharmacol Ther*. 2001; 90:45–60. [PubMed: 11448725]
- Powers MB, Smits JA, Otto MW, Sanders C, Emmelkamp PM. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. *J Anxiety Disord*. 2009; 23:350–6. [PubMed: 19223151]
- Poulton R, Menzies RG. Fears born and bred: Toward a more inclusive theory of fear acquisition. *Behav Res Ther*. 2002; 40:197–208. [PubMed: 11814183]
- Putman P, Van Honk J, Kessels RP, Mulder M, Koppeschaar HP. Salivary cortisol and short and long-term memory for emotional faces in healthy young women. *Psychoneuroendocrinology*. 2004; 29:953–60. [PubMed: 15177712]
- Quirk GJ, Garcia R, González-Lima F. Prefrontal mechanisms in extinction of conditioned fear. *Biol Psychiatry*. 2006; 60:337–43. [PubMed: 16712801]
- Quirk GJ, Russo GK, Barron JL, Lebron K. The role of ventromedial prefrontal cortex in the recovery of extinguished fear. *J Neurosci*. 2000; 20:6225–31. [PubMed: 10934272]
- Randall DC, Shneerson JM, Plaha KK, File SE. Modafinil affects mood, but not cognitive function, in healthy young volunteers. *Hum Psychopharmacol*. 2003; 18:163–73. [PubMed: 12672167]

- Rauch SL, Shin LM, Phelps EA. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research--past, present, and future. *Biol Psychiatry*. 2006; 60:376–82. [PubMed: 16919525]
- Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. *Arch Gen Psychiatry*. 2004; 61:1136–44. [PubMed: 15520361]
- Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. *Learn Mem*. 2004; 11:510–16. [PubMed: 15466301]
- Rohrer T, von Richthofen V, Schulz C, Beyer J, Lehnert H. The stress-, but not corticotropin-releasing hormone-induced activation of the pituitary-adrenal axis in man is blocked by alprazolam. *Horm Metab Res*. 1994; 26:200–06. [PubMed: 8082875]
- Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, Bystritsky A, Katon W, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. *Arch Gen Psychiatry*. 2005; 62:290–98. [PubMed: 15753242]
- Roy-Byrne, PP.; Cowley, DS. Pharmacological treatments for panic disorder, generalized anxiety disorder, specific phobia, and social anxiety disorder. In: Nathan, PE.; Gorman, JM., editors. *A Guide To Treatments That Work*. 2. New York, NY: Oxford University Press; 2002. p. 337-365.
- Salín-Pascual RJ, Basañez-Villa E. Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. *Rev Invest Clin*. 2003; 55:650–4. [PubMed: 15011734]
- Sareen J, Campbell DW, Leslie WD, Maliszka KL, Stein MB, Paulus MP, et al. Striatal function in generalized social phobia: a functional magnetic resonance imaging study. *Biol Psychiatry*. 2007; 61:396–404. [PubMed: 17097072]
- Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. *Science*. 1991; 251:947–50. [PubMed: 1825731]
- Schneider A, Huentelman MJ, Kremerskothen J, Duning K, Spoelgen R, Nikolich K. KIBRA: A New Gateway to Learning and Memory? *Front Aging Neurosci*. 2010; 2:4. [PubMed: 20552044]
- Schwartz JR, Hirshkowitz M, Erman MK, Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. *Chest*. 2003; 124:2192–99. [PubMed: 14665500]
- Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. *Prog Neurobiol*. 2004; 74:1–58. [PubMed: 15381316]
- Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti A, et al. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. *Neuropsychopharmacology*. 2003; 28:397–401. [PubMed: 12589394]
- Siegmund A, Köster L, Meves AM, Plag J, Stoy M, Ströhle A. Stress hormones during flooding therapy and their relationship to therapy outcome in patients with panic disorder and agoraphobia. *J Psychiatric Res*. (in press).
- Simon P, Panissaud C, Costentin J. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine. *Psychopharmacology*. 1994; 114:597–600. [PubMed: 7855221]
- Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tsan G, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neurotrophic factor. *Mol Psychiatry*. 2002; 76:579–93. [PubMed: 12140781]
- Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS, et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. *Science*. 2010; 327:863–6. [PubMed: 20075215]
- Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, et al. Glucocorticoids reduce phobic fear in humans. *Proc Natl Acad Sci USA*. 2006; 103:5585–90. [PubMed: 16567641]
- Stein DJ, Ludik J. A neural network of obsessive- compulsive disorder: modeling cognitive disinhibition and neurotransmitter dysfunction. *Med Hypotheses*. 2000; 55:168–76. [PubMed: 10904436]
- Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). *Cochrane Database Syst Rev*. 2006; 25:CD002795. [PubMed: 16437445]

- Stewart RE, Chambless DL. Cognitive-behavioral therapy for adult anxiety disorders in clinical practice: a meta-analysis of effectiveness studies. *J Consult Clin Psychol*. 2009; 77:595–606. [PubMed: 19634954]
- Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, et al. A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder. *Biol Psychiatry*. 2010 [Epub ahead of print].
- Ströhle A, Stoy M, Graetz B, Scheel M, Wittmann A, Gallinat J, Lang UE, Dimeo F, Hellweg R. Acute exercise ameliorates reduced brain-derived neurotrophic factor in patients with panic disorder. *Psychoneuroendocrinology*. 2010; 35:364–8. [PubMed: 19682803]
- Taneja I, Haman K, Shelton RC, Robertson D. A randomized, double-blind, crossover trial of modafinil on mood. *J Clin Psychopharmacol*. 2007; 27:76–9. [PubMed: 17224718]
- Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Räsänen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. *J Affect Disord*. 2004; 82:447–52. [PubMed: 15555697]
- van der Wee NJ, van Veen JF, Stevens H, van Vliet IM, van Rijk PP, Westenberg HG. Increased serotonin and dopamine transporter binding in psychotropic medication-naïve patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. *J Nucl Med*. 2008; 49:757–63. [PubMed: 18413401]
- Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, Riva MA, et al. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. *Mol Psychiatry*. 2002; 7:136–7. [PubMed: 11840305]
- Vinod KY, Hungund BL. Role of the endocannabinoid system in depression and suicide. *Trends Pharmacol Sci*. 2006; 27:539–45. [PubMed: 16919786]
- Viveros MP, Llorente R, Moreno E, Marco EM. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. *Behav Pharmacol*. 2005; 16:353–62. [PubMed: 16148439]
- Volkow ND, Fowler JS, Logan JS, Alexoff D, Zhu W, Telang F, et al. Effects of Modafinil on dopamine transporters in the male human brain: Clinical implication. *JAMA*. 2009; 299:1148–54. [PubMed: 19293415]
- Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. *J Neurosci*. 2002; 22:2343–51. [PubMed: 11896173]
- Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearson GD, Reese HE, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. *Am J Psychiatry*. 2008; 165:335–41. [PubMed: 18245177]
- Wong YN, King SP, Simcoe D, Gorman S, Loughton W, McCormick GC, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. *J Clin Pharmacol*. 1999; 39:281–8. [PubMed: 10073328]
- Yang YL, Chao PK, Ro LS, Wo YY, Lu KT. Glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. *Neuropsychopharmacology*. 2007; 32:1042–51. [PubMed: 17047672]
- Yu H, Wang Y, Pattwell S, Jing D, Liu T, Zhang Y, et al. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. *J Neuro*. 2009; 29:4056–64.
- Yun AJ, Doux JD, Daniel SM. Brewing controversies: Darwinian perspective on the adaptive and maladaptive effects of caffeine and ethanol as dietary autonomic modulators. *Med Hypotheses*. 2007; 68:31–6. [PubMed: 17195316]
- Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. *J Neurol*. 2002; 249:983–7. [PubMed: 12195441]

Table 1

Clinical applications of the cognitive enhancers

Authors (year)	Cognitive Enhancer	Disorder	Study Design	Results
Ressler et al. (2004)	DCS	Height phobia	50 mg or 250mg DCS or placebo administered prior to each of 2 virtual reality exposure sessions	Greater gains after DCS than placebo-augmented exposure sessions. No dose-response relationship
Hofmann et al. (2006)	DCS	SAD	50 mg DCS or placebo prior to each of 4 exposure sessions.	Greater gains with DCS than placebo-augmented exposure sessions.
Guastella et al. (2008)	DCS	SAD	50 mg DCS or placebo administered 1 hour prior to each of 4 social exposure sessions.	Greater gains with DCS than placebo-augmented exposure sessions.
Otto et al. (2009)	DCS	Panic Disorder	50 mg DCS or placebo administered 1 hour prior to each of 3 interoceptive exposure sessions	Greater gains with DCS than placebo-augmented exposure sessions.
Kushner et al. (2007)	DCS	OCD	125 mg DCS or placebo administered 2 hours prior to each of 10 exposure/ritual prevention sessions	Greater gains with DCS than placebo-augmented exposure sessions by mid-treatment. This effect weakened with continuous drug administration.
Wilhelm et al. (2008)	DCS	OCD	100 mg DCS or placebo administered 1 hour prior to each of 10 exposure/ritual prevention sessions.	Greater gains with DCS than placebo-augmented exposure sessions by mid-treatment. This effect weakened with continuous drug administration.
Storch et al. (2010)	DCS	OCD	250 mg DCS or placebo administered 4 hours prior to each of 12 exposure/ritual prevention sessions.	No evidence for treatment benefit of DCS versus placebo at post-test.
Powers et al. (2009)	Yohimbine	Claustrophobia	10.8 mg of Yohimbine or placebo administered prior to each of two exposure sessions.	Greater gains with yohimbine hydrochloride than placebo- augmented exposure sessions.
Soravia et al. (2006)	Cortisol	Spider phobia	10 mg of cortisol or placebo administered prior to each of 6 exposure sessions.	Greater fear reduction after cortisol than placebo-augmented exposure sessions.
Mystkowski et al. (2003)	Caffeine	Spider phobia	4mg/kg of body weight or placebo prior to 1 exposure session and then again at 1 week follow-up point.	Limited evidence for significant fear reduction versus placebo.

Note: DCS = D-cycloserine; SAD = Social Anxiety Disorder; OCD = Obsessive-Compulsive Disorder.